- Home
- LDWY vs APLM Comparison
LDWY vs APLM Comparison
Compare LDWY & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- APLM
- Stock Information
- Founded
- LDWY 1990
- APLM 2016
- Country
- LDWY United States
- APLM United States
- Employees
- LDWY N/A
- APLM N/A
- Industry
- LDWY Advertising
- APLM Blank Checks
- Sector
- LDWY Consumer Discretionary
- APLM Finance
- Exchange
- LDWY Nasdaq
- APLM Nasdaq
- Market Cap
- LDWY 6.7M
- APLM 7.7M
- IPO Year
- LDWY 1991
- APLM N/A
- Fundamental
- Price
- LDWY $4.12
- APLM $6.51
- Analyst Decision
- LDWY
- APLM Strong Buy
- Analyst Count
- LDWY 0
- APLM 1
- Target Price
- LDWY N/A
- APLM $200.00
- AVG Volume (30 Days)
- LDWY 3.9K
- APLM 57.8K
- Earning Date
- LDWY 05-19-2025
- APLM 04-03-2025
- Dividend Yield
- LDWY N/A
- APLM N/A
- EPS Growth
- LDWY N/A
- APLM N/A
- EPS
- LDWY N/A
- APLM N/A
- Revenue
- LDWY $37,773,000.00
- APLM $198,000.00
- Revenue This Year
- LDWY N/A
- APLM $415.15
- Revenue Next Year
- LDWY N/A
- APLM N/A
- P/E Ratio
- LDWY N/A
- APLM N/A
- Revenue Growth
- LDWY N/A
- APLM N/A
- 52 Week Low
- LDWY $3.02
- APLM $4.71
- 52 Week High
- LDWY $6.44
- APLM $53.00
- Technical
- Relative Strength Index (RSI)
- LDWY 62.30
- APLM 49.37
- Support Level
- LDWY $3.70
- APLM $5.41
- Resistance Level
- LDWY $4.23
- APLM $6.19
- Average True Range (ATR)
- LDWY 0.18
- APLM 0.77
- MACD
- LDWY 0.05
- APLM 0.08
- Stochastic Oscillator
- LDWY 56.24
- APLM 95.24
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.